Upstream Bio (UPB) Common Equity (2023 - 2026)

Upstream Bio's Common Equity history runs 4 years deep, the most recent figure standing at $304.0 million for Q1 2026.

• On a quarterly basis, Common Equity fell 31.78% year-over-year to $304.0 million in Q1 2026; TTM through Mar 2026 was $304.0 million, a 31.78% decrease from a year earlier, with the FY2025 full-year figure at $339.8 million, down 27.69% from the prior year.
• Common Equity slipped to $304.0 million in Q1 2026 per UPB's latest filing, from $339.8 million in the prior quarter.
• Across five years, Common Equity topped out at $469.9 million in Q4 2024 and bottomed at -$160.3 million in Q3 2024.
• The 4-year median for Common Equity is $304.0 million (2026), against an average of $151.9 million.
• Biggest YoY gain for Common Equity was 481.6% in 2024; the steepest drop was 42.87% in 2024.
• Year by year, Common Equity stood at -$123.1 million in 2023, then jumped by 481.6% to $469.9 million in 2024, then dropped by 27.69% to $339.8 million in 2025, then dropped by 10.53% to $304.0 million in 2026.
• Per Business Quant, the three latest UPB Common Equity figures stand at $304.0 million (Q1 2026), $339.8 million (Q4 2025), and $378.6 million (Q3 2025).